RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @NutritionMadeS3: Evidence indicates inflammation and lipids/lipoproteins are BOTH CVD risk factors so let's stop with the 'it's not the…
RT @NutritionMadeS3: Evidence indicates inflammation and lipids/lipoproteins are BOTH CVD risk factors so let's stop with the 'it's not the…
Evidence indicates inflammation and lipids/lipoproteins are BOTH CVD risk factors so let's stop with the 'it's not the cholesterol it's the inflammation' talking point 'it's not X it's Y' regarding multifactorial diseases tends to be misdirection https:/
I don’t think its unreasonable to check hs-CRP once on adequate therapy and now trying to figure out additional inflammatory/residual risk /2 https://t.co/BRhfObuZ9a
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
Very interesting Guide, not just for cardiologists but also for dermatologists, specially those with interest in psoriasis @DrJoelGelfand @luisrpadial
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
RT @JACCJournals: Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70…
Learn the benefits and risks associated with anti-inflammatory therapy in atherosclerotic risk in #JACC: https://t.co/d70Fuhwjep. https://t.co/pi4W600Uvz
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @RevEspCardiol: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk via @JACCJournals https://t.co/xqMnxGPtfZ htt…
RT @RevEspCardiol: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk via @JACCJournals https://t.co/xqMnxGPtfZ htt…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @RevEspCardiol: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk via @JACCJournals https://t.co/xqMnxGPtfZ htt…
RT @RevEspCardiol: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk via @JACCJournals https://t.co/xqMnxGPtfZ htt…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @RevEspCardiol: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk via @JACCJournals https://t.co/xqMnxGPtfZ htt…
RT @RevEspCardiol: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk via @JACCJournals https://t.co/xqMnxGPtfZ htt…
RT @RevEspCardiol: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk via @JACCJournals https://t.co/xqMnxGPtfZ htt…
Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk via @JACCJournals https://t.co/xqMnxGPtfZ https://t.co/d81veQjjGE
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @TKDsosyal: Great state-of-art review on the recent developments and clinical utility of 3D echocardiography. #echofirst https://t.co/UN…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
RT @JACCJournals: Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6o…
Know how to reduce inflammation to reduce atherosclerotic risk? Click here to brush up with #JACC: https://t.co/jg0o1fw6oi. https://t.co/c50bRJCbKd
Great state-of-art review on the recent developments and clinical utility of 3D echocardiography. #echofirst https://t.co/UNCc3H0mKA https://t.co/78gi88dWHh
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
RT @ValleAlfonso: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients…
Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk➡️ clinical implications of CANTOS for patients with “residual inflammatory risk” vía @JACCJournals 📎 https://t.co/NYYwAqhOb4 #RiesgoVascular @secardiologia https://t.co/OxMkejlcGq
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @TKDsosyal: Learn more about the potential benefits & risks of anti-inflammatory tx in #CVD and the future directions in the light of #C…
Learn more about the potential benefits & risks of anti-inflammatory tx in #CVD and the future directions in the light of #CANTOS trial. https://t.co/UNCc3H0mKA https://t.co/XEhUP6cZEK
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
Paul Ridker nicely summarises key sources of residual risk under #statin therapy in @JACCJournals review: #cholesterol, #inflammation, #thrombosis, #triglycerides and #lpa. @krychtiukmd thanks for pointing it out. Will include it in an upcoming presentatio
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
RT @krychtiukmd: Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Pro…
Clinician’s Guide to Reducing Inflammation to Reduce Atherothrombotic Risk - @JACCJournals review topic of the week by Prof. Ridker #Cardiology #Cardiotwitter #Inflammation #Atherosclerosis #Immunity #Immunology https://t.co/zQ6hHB1gLL https://t.co/2vsVs
We've come full circle! Inflammation/"Bad Humor" is bad! https://t.co/ANDoI8rj4z https://t.co/ffzJD14AOd
RT @mbelshazly: Great @JACCJournals review by Ridker re: reducing #inflammation to reduce ASCVD. Residual inflammatory risk is as important…
RT @mbelshazly: Great @JACCJournals review by Ridker re: reducing #inflammation to reduce ASCVD. Residual inflammatory risk is as important…
RT JACCJournals "RT mbelshazly: Great JACCJournals review by Ridker re: reducing #inflammation to reduce ASCVD. Residual inflammatory risk is as important as residual cholesterol risk. Will reducing lifelong burden of inflammation earlier in life lea… http
RT @mbelshazly: Great @JACCJournals review by Ridker re: reducing #inflammation to reduce ASCVD. Residual inflammatory risk is as important…
RT @mbelshazly: Great @JACCJournals review by Ridker re: reducing #inflammation to reduce ASCVD. Residual inflammatory risk is as important…
Great @JACCJournals review by Ridker re: reducing #inflammation to reduce ASCVD. Residual inflammatory risk is as important as residual cholesterol risk. Will reducing lifelong burden of inflammation earlier in life lead to improved long-term outcomes? htt
RT @vic_pallares: Yet many patients experience life-threatening first & recurrent cardiovascular events despite control of conventional ris…
RT @vic_pallares: Yet many patients experience life-threatening first & recurrent cardiovascular events despite control of conventional ris…
RT @vic_pallares: Yet many patients experience life-threatening first & recurrent cardiovascular events despite control of conventional ris…
RT @Dr_Manito: La diferencia entre CIRT (metotrexato) y CANTOS (canakinumab) está: Inclusión en CIRT no exigia riesgo inflamatorio residual…
RT @Dr_Manito: La diferencia entre CIRT (metotrexato) y CANTOS (canakinumab) está: Inclusión en CIRT no exigia riesgo inflamatorio residual…
RT @Dr_Manito: La diferencia entre CIRT (metotrexato) y CANTOS (canakinumab) está: Inclusión en CIRT no exigia riesgo inflamatorio residual…
La diferencia entre CIRT (metotrexato) y CANTOS (canakinumab) está: Inclusión en CIRT no exigia riesgo inflamatorio residual, canakinumab es selectivo y metotrexato no, por esto muchos pacientes CIRT: transaminitis, leucopenia, anemia e infecciones. Infl
Yet many patients experience life-threatening first & recurrent cardiovascular events despite control of conventional risk factors. More information #CANTOSTrial (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) https://t.co/vrE0sS8okd @SEMERG